Table 1 Baseline characteristics

From: Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction

 

Pre-2006 CAPOX 2000

Post-2006 CAPOX 1700

N

200

200

Median age (years) (range)

65 (23–83)

66 (23–87)

Aged⩾75 years

30 (15%)a

37 (19%)b

Aged <75 years

170 (85%)

163 (82%)

Gender

 Male

118 (59%)

121 (61%)

 Female

82 (41%)

79 (39%)

Race

 White

177 (89%)

186 (93%)

 Asian

8 (4%)

11 (6%)

 Black

11 (6%)

3 (2%)

 Others

4 (2%)

0 (0%)

Treatment intention

 (Neo)adjuvant

68 (34%)

48 (24%)

 Metastatic

132 (66%)

152 (76%)

Baseline eGFR

 Median (ml min–1) (range)

83 (31–151)

83 (40–214)

 <50 ml min–1

6 (3%)

5 (3%)

 50–70 ml min–1

44 (22%)

49 (25%)

 >70 ml min–1

150 (75%)

146 (73%)

  1. Abbreviations: CAPOX=capecitabine plus oxaliplatin; eGFR=estimated glomerular filtration rate.
  2. This table shows number of patients in each category unless otherwise stated (i.e. median age and median eGFR).
  3. aAged ⩾75 years and had capecitabine starting dose of 1500 mg m–2 per day instead of 2000 mg m–2 per day.
  4. bAged ⩾75 years and had capecitabine starting dose of 1300 mg m–2 per day instead of 1700 mg m–2 per day.
Back to article page